Pharma BD Deal Intelligence

Allergan plc / Vitae Pharmaceuticals, Inc.

2016 · Acquisition/Merger · $639M · Complete

Announcement Sentiment

Strongly positive

Allergan acquired Vitae Pharmaceuticals for $21.00/share, ~$639M total. Adds first-in-class oral RORgammaT inhibitor VTP-43742 (psoriasis) and topical LXRbeta agonist VTP-38543 (atopic dermatitis) plus Vitae's Contour drug discovery platform to Allergan's medical dermatology pipeline. Closed October 25, 2016.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Sep 14, 2016
Closed Oct 25, 2016
Deal value $639M
Deal type Acquisition/Merger
Therapeutic area Psoriasis and other autoimmune disorders (VTP-43742); atopic dermatitis (VTP-38543)
Indications Psoriasis and other autoimmune disorders (VTP-43742); atopic dermatitis (VTP-38543)
Key assets VTP-43742; VTP-38543
Mechanism Oral RORgammaT inhibitor (VTP-43742); topical LXRbeta agonist (VTP-38543)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals